Red Cell Distribution Width Versus Presepsin (Soluble CD14) as a Prognostic Marker in Critically-ill Sepsis Patients

Study Overview
=================
Brief Summary
-----------------
Presepsin (soluble CD14 subtype) is a novel marker with growing body of evidence supporting its accuracy and value for the diagnosis of sepsis. Patients with sepsis showed higher Prsepsin levels compared to those with SIRS. In addition the increase in Prsepsin levels correlates well with sepsis severity. Red cell distribution width variations are increased in a variety of medical conditions such as congestive heart failure, acute myocardial infarction, pulmonary embolism, pneumonia, critical illness, and cardiac arrest , and is a predictor of mortality in the general population. we aim to compare between Presepsin (soluble CD14) and RDW as prognostic markers in critically-ill patients with sepsis.

Official Title
-----------------
Comparison of Red Cell Distribution Width Versus Presepsin (Soluble CD14) for Prognosis Assessment in Sepsis Patients Admitted to the Intensive Care Unit

Conditions
-----------------
Sepsis

Intervention / Treatment
-----------------
* Diagnostic Test: Red Cell Distribution Width (RDW)
* Diagnostic Test: Presepsin (sCD14-ST)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female aged 18 65 years. Appropriate clinical data to enable classification into sepsis or SIRS according to Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Written informed consent by the patient or guardian Exclusion Criteria: No informed consent Renal failure Liver failure Hematologic diseases Neutropenia Malignancy Chemotherapy during the previous 90 days. Patients using antibiotics at presentation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Red Cell Distribution Width (RDW)<br>RDW was assessed as part of complete blood count analysis using SYSMEX XN-550 automated analyzer | Diagnostic Test: Red Cell Distribution Width (RDW)<br>* A total of 100 sepsis patients, Red Cell Distribution Width (RDW) was used as prognostic marker.<br>|
| Presepsin (sCD14-ST)<br>Presepsin analysis was done by utilising Elisa technique using kits from (MyBioSource, San Diego, CA 92195-3308 USA) | Diagnostic Test: Presepsin (sCD14-ST)<br>* : A total of 100 sepsis patients, Presepsin (sCD14-ST) was used as prognostic marker.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality during intensive care unit stay |  | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of ICU stay |  | assessed up to 3 months | 
| Need for readmission to ICU |  | assessed up to 3 months | 
| Ventilatory support duration |  | assessed up to 3 months | 
| Number of participants who need renal replacement therapy |  | assessed up to 3 months | 
| Number of participants who need inotropic or vasopressor support |  | assessed up to 3 months | 
| Transfusion requirements (blood and blood products) |  | assessed up to 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sepsis, presepsin, red cell distribution width